Skip to main content
. 2021 Nov 23;8:782231. doi: 10.3389/fmed.2021.782231

Table 2.

Status of subjects receiving immunosuppressive therapy.

Subjects number Drug Cycle(s) Interval between PET/CT month(s)* SUVmax of thyroid TBR
2 Rituximab 4 2 3 4.9
9 Navuliumab 3 1 4.2 7.64
17 Carrelizumab 1 1 6.1 7.46
*

The interval between PET/CT examination and the end of the previous cycle of treatment.